Vascular Biogenics Ltd (VBLT)

[wcopeland]

No, Valueinvestor12, I do not think that DSMC's report will stop the trial for early approval. Also, they have probably achieved both 105 deaths and 50% with 12-month data by now. I imagine they would be given a few weeks to perform the interim analysis, so if their interim would have coincided with the DSMC report, the interim trigger likely happened. That said, skipping the Ph3 interim is really weird. How often does that happen?

Gr8, I agree, I think things are all positive still. Longer survival is likely attributable to VB111. If patients in the Avastin arm are living longer, it is probably because they drop out of the trial in favor of some other treatment rather than Avastin extremely outperforming. I would guess it would be nice to do an analysis of concurrent rGBM trials.